News
Clinical Trials Arena on MSN12h
FDA clears Caliway’s trial of CBL-514 for localised fat reduction
The top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.
Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...
Caliway receives US FDA clearance to proceed with SUPREME-01 phase 3 study of CBL-514 for reducing abdominal subcutaneous fat: New Taipei City Tuesday, July 29, 2025, 14:00 Hrs [I ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Fashionista on MSN8h
'GLP-1 Beauty' Is Here — But Is it a Marketing Gimmick?
As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback